enzalutamide
Selected indexed studies
- ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer. (J Clin Oncol, 2019) [PMID:31329516]
- Enzalutamide plus radium-223 in metastatic castration-resistant prostate cancer: results of the EORTC 1333/PEACE-3 trial. (Ann Oncol, 2025) [PMID:40450503]
- Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer. (N Engl J Med, 2018) [PMID:29949494]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Comparison of abiraterone, enzalutamide, and apalutamide for metastatic hormone-sensitive prostate cancer: A multicenter study. (2025) pubmed
- Matching-adjusted indirect comparison of enzalutamide versus darolutamide doublet in mHSPC. (2025) pubmed
- ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer. (2019) pubmed
- Enzalutamide plus radium-223 in metastatic castration-resistant prostate cancer: results of the EORTC 1333/PEACE-3 trial. (2025) pubmed
- Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer. (2018) pubmed
- Enzalutamide Sensitizes Castration-Resistant Prostate Cancer to Copper-Mediated Cell Death. (2024) pubmed
- Increased survival with enzalutamide in prostate cancer after chemotherapy. (2012) pubmed
- Talazoparib plus enzalutamide in men with metastatic castration-resistant prostate cancer: final overall survival results from the randomised, placebo-controlled, phase 3 TALAPRO-2 trial. (2025) pubmed
- [(177)Lu]Lu-PSMA-617 plus enzalutamide in patients with metastatic castration-resistant prostate cancer (ENZA-p): an open-label, multicentre, randomised, phase 2 trial. (2024) pubmed
- TALAPRO-3 clinical trial protocol: phase III study of talazoparib plus enzalutamide in metastatic castration-sensitive prostate cancer. (2024) pubmed